Beach Investment Counsel Increased Its Enterprise Prod Partners (EPD) Holding; Acelrx Pharmaceuticals (ACRX)’s Sentiment Is 0.75

November 15, 2017 - By Peter Erickson

AcelRx Pharmaceuticals, Inc. is a pharmaceutical firm focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The company has market cap of $93.13 million. The Firm operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. It currently has negative earnings. The Company’s lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03.

Beach Investment Counsel Inc increased Enterprise Prod Partners (EPD) stake by 4.08% reported in 2017Q2 SEC filing. Beach Investment Counsel Inc acquired 75,190 shares as Enterprise Prod Partners (EPD)’s stock declined 6.06%. The Beach Investment Counsel Inc holds 1.92 million shares with $52.00M value, up from 1.85 million last quarter. Enterprise Prod Partners now has $51.70B valuation. The stock decreased 1.21% or $0.3 during the last trading session, reaching $24.06. About shares traded. Enterprise Products Partners L.P. (NYSE:EPD) has declined 0.18% since November 15, 2016 and is downtrending. It has underperformed by 16.88% the S&P500.

Among 24 analysts covering Enterprise Products Partners LP (NYSE:EPD), 23 have Buy rating, 0 Sell and 1 Hold. Therefore 96% are positive. Enterprise Products Partners LP has $38 highest and $29 lowest target. $32.20’s average target is 33.83% above currents $24.06 stock price. Enterprise Products Partners LP had 46 analyst reports since July 23, 2015 according to SRatingsIntel. The stock has “Buy” rating by Deutsche Bank on Monday, October 10. BMO Capital Markets maintained Enterprise Products Partners L.P. (NYSE:EPD) on Tuesday, August 15 with “Buy” rating. On Monday, April 24 the stock rating was maintained by Macquarie Research with “Outperform”. On Friday, September 16 the stock rating was initiated by Evercore with “Buy”. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, July 13. As per Tuesday, August 18, the company rating was downgraded by Vetr. The rating was initiated by Howard Weil on Wednesday, January 6 with “Sector Outperform”. Jefferies maintained the shares of EPD in report on Wednesday, April 5 with “Buy” rating. The stock has “Overweight” rating by Barclays Capital on Friday, August 4. The firm has “Overweight” rating given on Friday, April 1 by Piper Jaffray.

Investors sentiment decreased to 0.99 in Q2 2017. Its down 0.06, from 1.05 in 2017Q1. It is negative, as 54 investors sold EPD shares while 250 reduced holdings. 58 funds opened positions while 244 raised stakes. 780.09 million shares or 1.82% more from 766.14 million shares in 2017Q1 were reported. Cibc Asset Incorporated invested in 63,829 shares. Advisory Gru reported 0.1% in Enterprise Products Partners L.P. (NYSE:EPD). Clearbridge Investments Ltd invested in 0.44% or 16.67 million shares. Suntrust Banks invested 0.02% of its portfolio in Enterprise Products Partners L.P. (NYSE:EPD). Tradewinds Ltd Liability Company has invested 0.01% in Enterprise Products Partners L.P. (NYSE:EPD). Groesbeck Nj reported 1.03% stake. Ipswich Investment stated it has 0.12% in Enterprise Products Partners L.P. (NYSE:EPD). Moreover, Tortoise Invest Mngmt Ltd has 0.01% invested in Enterprise Products Partners L.P. (NYSE:EPD) for 900 shares. Airain reported 0.04% in Enterprise Products Partners L.P. (NYSE:EPD). Fisher Asset Mgmt Lc has 8,999 shares for 0% of their portfolio. 34,121 were accumulated by Barnett And. Pnc Ser Inc reported 0.09% stake. First Western Cap invested in 25,331 shares. Parsons Capital Management Inc Ri invested 0.03% of its portfolio in Enterprise Products Partners L.P. (NYSE:EPD). Tocqueville Asset Mngmt Lp holds 44,071 shares or 0.01% of its portfolio.

Analysts await AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to report earnings on March, 1. They expect $-0.22 earnings per share, down 4.76% or $0.01 from last year’s $-0.21 per share. After $-0.28 actual earnings per share reported by AcelRx Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -21.43% EPS growth.

About 18,000 shares traded. AcelRx Pharmaceuticals Inc (ACRX) has declined 14.24% since November 15, 2016 and is downtrending. It has underperformed by 30.94% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By :